clinical trial · NCT06460493
Effect of Ensifentrine Treatment on CAT Score
COPDEnsifentrine 3 mg twice daily
brief summary
The purpose of this open-label, single center trial is to assess the effect of twice daily nebulized ensifentrine (3 mg) on COPD symptoms measured by the COPD Assessment Test (CAT™) scores over 12 weeks in subjects with symptomatic, moderate to severe COPD, taking maintenance LAMA/LABA or LAMA/LABA/ICS therapy. Subjects will continue the maintenance treatment during study participation.
started
Jun 11, 2024
primary completion
Nov 26, 2024
completion
Dec 3, 2024
last updated
Apr 18, 2025
official title
A Study Assessing the Effect of Ensifentrine on CAT™ Scores Over 12 Weeks in Subjects With Moderate to Severe COPD
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol